These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 19939929)
1. Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. Mueller SN; Langley WA; Carnero E; García-Sastre A; Ahmed R J Virol; 2010 Feb; 84(4):1847-55. PubMed ID: 19939929 [TBL] [Abstract][Full Text] [Related]
2. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H mBio; 2019 Sep; 10(5):. PubMed ID: 31530680 [TBL] [Abstract][Full Text] [Related]
3. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. Nogales A; DeDiego ML; Topham DJ; Martínez-Sobrido L J Virol; 2016 Jul; 90(14):6291-6302. PubMed ID: 27122587 [TBL] [Abstract][Full Text] [Related]
4. Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses. Wang Z; Kedzierski L; Nuessing S; Chua BYL; Quiñones-Parra SM; Huber VC; Jackson DC; Thomas PG; Kedzierska K J Gen Virol; 2016 Dec; 97(12):3205-3214. PubMed ID: 27902386 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs. Kappes MA; Sandbulte MR; Platt R; Wang C; Lager KM; Henningson JN; Lorusso A; Vincent AL; Loving CL; Roth JA; Kehrli ME Vaccine; 2012 Jan; 30(2):280-8. PubMed ID: 22067263 [TBL] [Abstract][Full Text] [Related]
7. Viral Subpopulation Screening Guides in Designing a High Interferon-Inducing Live Attenuated Influenza Vaccine by Targeting Rare Mutations in NS1 and PB2 Proteins. Ghorbani A; Abundo MC; Ji H; Taylor KJM; Ngunjiri JM; Lee CW J Virol; 2020 Dec; 95(2):. PubMed ID: 33115873 [TBL] [Abstract][Full Text] [Related]
8. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. Nogales A; Baker SF; Ortiz-Riaño E; Dewhurst S; Topham DJ; Martínez-Sobrido L J Virol; 2014 Sep; 88(18):10525-40. PubMed ID: 24965472 [TBL] [Abstract][Full Text] [Related]
9. Qualitatively different memory CD8+ T cells are generated after lymphocytic choriomeningitis virus and influenza virus infections. Mueller SN; Langley WA; Li G; García-Sastre A; Webby RJ; Ahmed R J Immunol; 2010 Aug; 185(4):2182-90. PubMed ID: 20639484 [TBL] [Abstract][Full Text] [Related]
10. A Promising IFN-Deficient System to Manufacture IFN-Sensitive Influenza Vaccine Virus. Chen C; Fan W; Li J; Zheng W; Zhang S; Yang L; Liu D; Liu W; Sun L Front Cell Infect Microbiol; 2018; 8():127. PubMed ID: 29765910 [TBL] [Abstract][Full Text] [Related]
11. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene. Choi EH; Song MS; Park SJ; Pascua PN; Baek YH; Kwon HI; Kim EH; Kim S; Jang HK; Poo H; Kim CJ; Choi YK Arch Virol; 2015 Jul; 160(7):1729-40. PubMed ID: 25959557 [TBL] [Abstract][Full Text] [Related]
12. Attenuated influenza virus vaccines with modified NS1 proteins. Richt JA; García-Sastre A Curr Top Microbiol Immunol; 2009; 333():177-95. PubMed ID: 19768406 [TBL] [Abstract][Full Text] [Related]
13. Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Nogales A; Huang K; Chauché C; DeDiego ML; Murcia PR; Parrish CR; Martínez-Sobrido L Virology; 2017 Jan; 500():1-10. PubMed ID: 27750071 [TBL] [Abstract][Full Text] [Related]
14. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. Richt JA; Lekcharoensuk P; Lager KM; Vincent AL; Loiacono CM; Janke BH; Wu WH; Yoon KJ; Webby RJ; Solórzano A; García-Sastre A J Virol; 2006 Nov; 80(22):11009-18. PubMed ID: 16943300 [TBL] [Abstract][Full Text] [Related]
15. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745 [TBL] [Abstract][Full Text] [Related]
16. Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA. Li J; Arévalo MT; Diaz-Arévalo D; Chen Y; Choi JG; Zeng M J Control Release; 2015 Jun; 207():70-6. PubMed ID: 25858415 [TBL] [Abstract][Full Text] [Related]
17. Cross-clade protective immune responses of NS1-truncated live attenuated H5N1 avian influenza vaccines. Shi S; Chen S; Han W; Wu B; Zhang X; Tang Y; Wang X; Zhu Y; Peng D; Liu X Vaccine; 2016 Jan; 34(3):350-7. PubMed ID: 26638027 [TBL] [Abstract][Full Text] [Related]
18. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. Steel J; Lowen AC; Pena L; Angel M; Solórzano A; Albrecht R; Perez DR; García-Sastre A; Palese P J Virol; 2009 Feb; 83(4):1742-53. PubMed ID: 19073731 [TBL] [Abstract][Full Text] [Related]
19. Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Chambers TM; Quinlivan M; Sturgill T; Cullinane A; Horohov DW; Zamarin D; Arkins S; García-Sastre A; Palese P Equine Vet J; 2009 Jan; 41(1):87-92. PubMed ID: 19301588 [TBL] [Abstract][Full Text] [Related]
20. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]